Barrett oesophagus in 2013: risk stratification and surveillance in Barrett oesophagus
- PMID: 24322896
- PMCID: PMC4479384
- DOI: 10.1038/nrgastro.2013.237
Barrett oesophagus in 2013: risk stratification and surveillance in Barrett oesophagus
Abstract
Advances are being made in understanding the pathogenesis, treatment outcomes and surveillance of Barrett oesophagus. Central obesity and age at onset of gastro-oesophageal reflux are being recognized as risk factors that have implications for screening. The persistent finding of nondysplastic Barrett oesophagus during surveillance is associated with low risk of malignant progression, whereas dysplastic Barrett oesophagus requires continued surveillance.
Conflict of interest statement
E. C. Gorospe declares associations with the following company: Boston Scientific. K. K. Wang declares associations with the following companies: CDX Diagnostics; Covidien; CSA Medical; Fujinon; Ninepoint Medical. See the article online for full details of the relationships.
References
-
- Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19:1468–1470. - PubMed
-
- Robertson EV, et al. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology. 2013;145:730–739. - PubMed
-
- Cook MB. Optimization and expansion of predictive models for Barrett’s esophagus and esophageal adenocarcinoma: could a life-course exposure history be beneficial? Am J Gastroenterol. 2013;108:923–925. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
